Gastrointestinal Stromal Tumor (GIST)
Oncology
2
Pipeline Programs
3
Companies
3
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Small Molecule
2100%
+ 1 programs with unclassified modality
Competitive Landscape
3 companies ranked by most advanced pipeline stage
Astex PharmaceuticalsUK - Cambridge
1 program1
AT13387 and ImatinibPhase 2Small Molecule1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
2028
Astex PharmaceuticalsAT13387 and Imatinib
Kura Oncologyziftomenib
Heidelberg PharmaDual Energy CT
Clinical Trials (3)
Total enrollment: 250 patients across 3 trials
A Study to Investigate the Safety and Efficacy of AT13387, Alone or in Combination With Imatinib, in Patients With GIST
Start: Mar 2011Est. completion: Jul 2014
Phase 2Completed
A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
Start: Mar 2025Est. completion: Dec 2028157 patients
Phase 1Recruiting
Unifying Advanced Treatment With Advanced Imaging
Start: Dec 2014Est. completion: Dec 202093 patients
N/ACompleted
Related Jobs in Oncology
Senior Research Associate, Immuno-Oncology
SystImmune
2h ago
$60K - $85K/yr
Research Associate I/II, Immuno-Oncology
SystImmune
2h ago
Office Administrator
SystImmune
2h ago
$60K - $80K/yr
Scientist/Sr Scientist
TwoStep Therapeutics
San Carlos
3h ago
Senior Medical Project Manager (m/f/d)
Mindpeak
Hamburg
3h ago
Working Student Active Sourcing Support (m/f/d)
Mindpeak
Hamburg
3h ago
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 250 patients
Small Molecule is the dominant modality (100% of programs)
3 companies competing in this space